Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Topotecan + Docetaxel for Recurrent SCLC
NCT00315211Phase 2Terminated
- Sponsor
- Aultman Health Foundation
- Start
- Nov 2004
- Primary completion
- Jun 2007
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan liposome in small cell lung cancer (SCLC), sponsored by Aultman Health Foundation. Primary endpoint: Overall Response Rate at 3 years. Started Nov 2004; status: terminated.
02
Drugs
topotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00315211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00315211.